CompletedNCT01986114
A Long-Term Study of SM-13496 in Patients With Bipolarity type I.
Medication studyAges 18–74Multiple countries
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 74 years. Other eligibility criteria applied.
- Listed locations
- Tokyo and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: January 29, 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 495
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan, Lithuania, Malaysia, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT01986114
- Official title
Show the full official title
A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.
Get this study by email
Recruitment & locations
CompletedTokyo, Japan · Kaunas, Lithuania · Kuala Lumpur, Malaysia
6 more locations
- Manila, Philippines
- Moscow, Russia
- Žilina, Slovakia
- Taipei, Taiwan
- Kiev, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SM-13496.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 74 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
A Cariprazine Study in the Prevention of Relapse in Bipolarity type I Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features